OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events

Item 8.01. Other Events.

OWC Pharmaceutical Research Corp. (the Registrant) is reporting
the issuance on June 27, 2017 of the attached press release,
announcing that its wholly-owned, Israel-based subsidiary, One
World Cannabis Ltd (OWC), has filed a patent application with the
United States Patent and Trademark Office for its active
cannabinoid-based topical cream. This new patent application
follows the previously filed provisional patent application. The
added protection that this patent application should provide for
OWC’s intellectual property will enable OWC to accelerate its
ongoing discussions and negotiations regarding scientific,
medical and commercial collaboration, based upon the fact that
OWC’s topical cream is ready for marketing and commercial
exploitation.

Reference is made to the full text of the press release filed as
Exhibit 99.1 herewith.

Item 9.01 Financial Statements and Exhibits.

(a) The following documents are filed as exhibits to this report
on Form 8-K or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical
reference to the SEC filing that included such document.

OWC Pharmaceutical Research Corp. Exhibit
EX-99 2 exh99_1.htm PRESS RELEASE OWC Pharmaceutical Research Corp. announces market readiness of its cannabinoid-based topical cream for skin conditions starting with Psoriasis. The Company has filed a full patent with The United States Patent and Trademark Office [USPTO] Patent Application Number: 15/639,…
To view the full exhibit click here
About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.